Advanced search
Publication Cover
Journal of Dermatological Treatment Volume 33, 2022 - Issue 1
Submit an article Journal homepage
988
Views
18
CrossRef citations to date
0
Altmetric
Articles

Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review

T. Montero-Vilcheza Hidradenitis Suppurativa Clinic, Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain;b Instituto de Investigación Biosanitaria IBS, Granada, SpainORCID Iconhttps://orcid.org/0000-0003-4035-7955
ORCID Icon,
T. Pozo-Románc Servicio de Dermatología, Hospital Universitario Rio Ortega, Valladolid, Spain
,
L. Sánchez-Veliciac Servicio de Dermatología, Hospital Universitario Rio Ortega, Valladolid, Spain
,
J. Vega-Gutiérrezc Servicio de Dermatología, Hospital Universitario Rio Ortega, Valladolid, Spain
,
S. Arias-Santiagoa Hidradenitis Suppurativa Clinic, Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain;b Instituto de Investigación Biosanitaria IBS, Granada, SpainCorrespondence[email protected]
&
A. Molina-Leyvaa Hidradenitis Suppurativa Clinic, Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain;b Instituto de Investigación Biosanitaria IBS, Granada, Spain;d European Hidradenitis Suppurativa Foundation (EHSF), Dessau-Roßlau, Germany
Pages 348-353 | Received 09 Mar 2020, Accepted 05 Apr 2020, Published online: 21 Apr 2020

References

  • Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619–644.
  • Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539–561.
  • Danby FW, Jemec GBE, Marsch WC, et al. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013;168(5):1034–1039.
  • Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. J Eur Acad Dermatol Venereol. 2016;30(6):989–994.
  • van der Zee HH, de Ruiter L, van den Broecke DG, et al. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292–1298.
  • Schlapbach C, Hänni T, Yawalkar N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790–798.
  • Zouboulis CC, Bechara FG, Dickinson-Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31.
  • Gulliver WP, Jemec GBE, Baker KA. Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa. J Eur Acad Dermatology Venereol. 2012;26(7):911–914.
  • Romaní J, Vilarrasa E, Martorell A, et al. Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa. Dermatology. 2020;236(Suppl. 1):21–24.
  • Scholl L, Hessam S, Garcovich S, et al. High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. Eur J Dermatol. 2019;29(6):659–661.
  • Takeda K, Kikuchi K, Kanazawa Y, et al. Ustekinumab treatment for hidradenitis suppurativa. J Dermatol. 2019;46(12):1215–1218.
  • Baerveldt EM, Kappen JH, Thio HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behçet’s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626–627.
  • Blok JL, Li K, Brodmerkel C, et al. Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum. Br J Dermatol. 2016;174(4):839–846.
  • Santos-Pérez MI, García-Rodicio S, Del Olmo-Revuelto MA, et al. Ustekinumab en hidradenitis supurativa: a propósito de un caso. Actas Dermosifiliogr. 2014;105(7):720–722.
  • Sharon VR, Garcia MS, Bagheri S, et al. Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venerol. 2012;92(3):320–321.
  • Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.